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We noticed overrepresentation of atovaquone-progua-
nil therapeutic failures among Plasmodium falciparum–in-
fected travelers weighing >100 kg. We report here 1 of 
these cases, which was not due to resistant parasites or 
impaired drug bioavailability. The follow-up of such patients 
should be strengthened.
F
ewer than 25 cases of falciparum malaria that failed 
to respond to atovaquone-proguanil (A-P) have been 
noted in published articles since the 1996 registration of 
Malarone (GlaxoSmithKline, Marly-le-Roi, France) (1,2). 
Well-documented cases that were not attributed to subop-
timal dosage or impaired bioavailability essentially due to 
vomiting, diarrhea, or both showed atovaquone-resistant 
parasites in the recrudescent isolate, with Y268S or Y268N 
cytochrome b mutations (2–10). We report the case of 
treatment failure that was not due to resistant parasites or 
impaired drug bioavailability.
The Case
During February 2007, a 39-year-old man who was 
born in Africa but lived in France since 1996 traveled to 
Kinshasa, Democratic Republic of Congo, for a 1-month 
vacation in which he visited friends and relatives. He was 6 
feet tall with strong musculature and weighed 115 kg (body 
mass index = 34.3). He did not use chemoprophylaxis and 
did not take antimalarial self-treatment before seeking 
medical advice. Two days after returning to France, a fever 
and other signs of uncomplicated malaria attack developed 
(chills, arthralgia, asthenia) without vomiting. Three days 
after onset of symptoms, the patient sought care at the Avi-
cenne Hospital, Bobigny, France. Blood smears performed 
at admission showed 1.6% Plasmodium falciparum parasit-
emia. The patient was hospitalized and immediately treat-
ed with the standard dosage of A-P (Malarone, 4 tablets 
each day for 3 days given with the main meal; each tablet 
contains 250 mg of atovaquone and 100 mg of proguanil 
hydrochloride). The patient experienced no vomiting or 
diarrhea. His fever abated by day 3 of treatment, and ma-
laria smears at that time showed 0.07% of morphologically 
altered parasites (these ﬁ  gures are not uncommon because 
A-P is known to act relatively slowly). The patient was dis-
charged on day 3. The patient did not return until his sched-
uled appointments for control of parasitemia on days 7 and 
28. The patient was apyretic, and parasitemia was negative 
by day 7 on thin and thick blood smears. On day 28, the 
patient was apyretic, but thin and thick smears showed P. 
falciparum trophozoites (0.001% parasitemia on thin smear 
and 16 trophozoites per 1,000 leukocytes on thick smear). 
The patient was then successfully retreated with 650 mg 
quinine base orally 3× daily for 7 days.
Day 0 in vitro phenotype showed parasite suscepti-
bility to atovaquone, with a 50% inhibitory concentration 
(IC50) value of 10 nmol/L (in vitro resistance threshold >40 
nmol/L [11]). Day 28 in vitro susceptibility was not assayed 
because of insufﬁ  cient parasite density. DNA sequencing 
showed that both day 0 and day 28 isolates had wild-type 
sequence of cytochrome b. Genotyping of the pfdhfr gene 
showed that the 3 major pfdhfr mutations (at position 51, 59, 
and 108) associated with cycloguanil resistance were found 
in isolates from day 0 and day 28. The number and the pro-
portions of genotypes within isolates were determined by 
a fragment analysis method based on the polymorphism of 
the gene encoding merozoite surface protein-2 (12). Day 0 
and day 28 isolates contained the same majority genotype, 
with the 727-bp msp-2 allele representing >80% of iso-
lates. This parasite population analysis did not show the se-
lection of a minority-resistant genotype by A-P treatment. 
These results did not show either the emergence of mutant 
codon 268 cytochrome b within the 727-bp msp-2 domi-
nant genotype. High-performance liquid chromatography 
on day 3 of treatment (performed 20 h after the last drug 
intake) showed an atovaquone plasma concentration of 3.1 
μg/mL. High interpatient variability has been reported, but 
this value showed initial adequate drug concentration and 
excluded impaired bioavailability (13).
Thus, this patient, who had correctly taken A-P tab-
lets with food and did not vomit, showed correct plasma 
drug concentration on day 3 but did not show clearance of 
A-P–susceptible parasites on day 28, although he was as-
ymptomatic. Reinfection was excluded because the patient 
was treated after returning to France (which is a non–ma-
laria-endemic area). All these data suggest that the standard 
drug regimen led to suboptimal dosage in this patient. Ap-
parently correct initial atovaquone concentration on day 3 
did not predict the outcome of treatment because A-P acts 
slowly, and most reported A-P therapeutic failures were 
late failures. Drug interactions that could have lowered A-P 
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plasmatic concentration were excluded because, other than 
A-P, the patient received only acetaminophen.
Conclusions
The most plausible cause of this late therapeutic failure 
is the relatively insufﬁ  cient dosage due to increased oral 
clearance and volume of distribution of atovaquone in this 
patient who weighed >100 kg. According to the relation-
ships between oral clearance of atovaquone and weight, and 
between volume of distribution and weight, these param-
eters increase by 40% in comparison to those in a patient 
of 70 kg (13). The effect may be less marked for proguanil 
because, unlike atovaquone, it becomes concentrated in the 
erythrocytes. However, proguanil likely does not act by it-
self in A-P association but only facilitates the atovaquone 
activity (14). Likewise, the observed pfdhfr triple mutant 
likely had no effect on the intrinsic activity of proguanil 
but only reﬂ  ected the high frequency of this haplotype in 
West Africa.
Another hypothesis is that the treatment failure was 
due to resistant parasites not related to the cytochrome b 
mutations. Some rare therapeutic failures remain unex-
plained by phenotypic or genotypic data. Such a parasite 
should have emerged during treatment, because the IC50 of 
the day 0 isolate was susceptible. We know of only 1 other 
reported case of A-P treatment failure not associated with 
cytochrome b mutations and not related to incorrect dos-
age or impaired bioavailability (15). In the case reported 
by Wichmann et al. (15), clonal analysis of pre- and post-
treatment isolates was not performed, which limited the in-
terpretation of DNA sequencing; the weight of the patient 
was not mentioned.
Most previously reported A-P therapeutic failures 
were late failures: patients sought care or parasitemia was 
detected >3 weeks after ﬁ  rst day of treatment in 13 of 21 
cases (2–5,7–9,15). These data underline the usefulness of 
the day 28 appointment in detecting late A-P therapeutic 
failures. In addition, this appointment may provide the op-
portunity to detect asymptomatic parasitemia (2), as oc-
curred in the present case.
We noticed an overrepresentation of A-P therapeutic 
failures among patients who weighed >100 kg. In a series 
of 347 P. falciparum–infected travelers, 3 of 12 patients 
who weighed 100–115 kg exhibited therapeutic failure 
while receiving the standard A-P regimen (only 2 therapeu-
tic failures were reported among the other 335 patients who 
weighed <100 kg). Two of these patients >100 kg showed 
mutant parasites on the date treatment failure was recog-
nized (2); the third treatment failure (the present one) was 
due to susceptible parasites. Thus, relative suboptimal dos-
age of the standard A-P regimen in patients >100 kg led to 
either failure to control susceptible parasites or emergence 
of resistant ones. DNA point mutations conferring atova-
quone resistance may emerge more easily in patient who 
have received suboptimal dosage. However, not all patients 
weighing >100 kg seen in our center had A-P therapeutic 
failures. Eleven of these 12 patients were from Africa and 
could have possessed residual immunity, which could have 
helped them clear parasites.
A-P is safe and therapeutic failure remains rare. Nev-
ertheless, the overrepresentation of failures in patients 
>100 kg argues for strengthening the follow-up monitoring 
of those patients. Moreover, the weight of a patient could 
be taken into account in the dosage of A-P prescribed for 
similar cases in the future.
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